Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Clinical Pharmacology and Therapeutics

Volumn 104, Issue 2, 2018, Pages 364-373

  Kim, Hanna ^a   Brooks, Kristina M ^b   Tang, Cheng Cai ^c   Wakim, Paul ^b   Blake, Mary ^a   Brooks, Stephen R ^a   Montealegre Sanchez, Gina A ^d   de Jesus, Adriana A ^d   Huang, Yan ^d   Tsai, Wanxia Li ^a   Gadina, Massimo ^a   Prakash, Apurva ^e   Janes, Jonathan Marcus ^e   Zhang, Xin ^e   Macias, William L ^e   Kumar, Parag ^b   Goldbach Mansky, Raphaela ^d  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARICITINIB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; STAT3 PROTEIN; AZETIDINE DERIVATIVE; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; SULFONAMIDE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ARTICLE; BK VIRUS INFECTION; BODY SURFACE; BODY WEIGHT; BONE NECROSIS; CD4+ T LYMPHOCYTE; CHILD; CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WITH LIPODYSTROPHY AND ELEVATED TEMPERATURE; CLINICAL ARTICLE; COMPASSIONATE USE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HERPES ZOSTER; HUMAN; IC50; LIPODYSTROPHY; MALE; MAXIMUM CONCENTRATION; MORNING DOSAGE; NEUTROPHILIA; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKIN DISEASE; STING ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY; TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TROUGH CONCENTRATION; VASCULAR DISEASE; VIREMIA; VOLUME OF DISTRIBUTION; AGE; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; DOSE CALCULATION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; GLOMERULUS FILTRATION RATE; INFANT; INFLAMMATION; METABOLISM; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; AUTOIMMUNE DISEASES; AZETIDINES; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; COMPASSIONATE USE TRIALS; DRUG DOSAGE CALCULATIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; INFLAMMATION; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITORS; MALE; MODELS, BIOLOGICAL; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85049859371     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.936     Document Type: Article

References (38)

1. de Jesus, A.A., Canna, S.W., Liu, Y. & Goldbach-Mansky, R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu. Rev. Immunol. 33, 823–874 (2015)
2. Crow, Y.J. & Manel, N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15, 429–440 (2015)
3. Liu, Y. et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64, 895–907 (2012)
4. Agarwal, A.K. et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am. J. Hum. Gen. 87, 866–872 (2010)
5. Arima, K. et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl. Acad. Sci. U. S. A. 108, 14914–14919 (2011)
6. Kitamura, A. et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J. Clin. Invest. 121, 4150–4160 (2011)
7. Brehm, A. et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 125, 4196–4211 (2015)
8. Crow, Y.J. Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238, 91–98 (2011)
9. Kim, H., Sanchez, G.A. & Goldbach-Mansky, R. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J. Mol. Med. (Berl.) 94, 1111–1127 (2016)
10. Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P. & O'Shea, J.J. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 12, 464–470 (2012)
11. O'Shea, J.J., Gadina, M. & Schreiber, R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl.), S121–S131 (2002)
12. Igaz, P., Toth, S. & Falus, A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm. Res. 50, 435–441 (2001)
13. Shi, J.G. et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J. Clin. Pharmacol. 54, 1354–1361 (2014)
14. Center for Drug Evaluation and Research (CDER), F.D.A. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products, Guidance for Industry (2014)
15. Roberts, R., Rodriguez, W., Murphy, D. & Crescenzi, T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290, 905–911 (2003)
16. Sibley, C.H. et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64, 2375–2386 (2012)
17. Goldbach-Mansky, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355, 581–592 (2006)
18. Neven, B. et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62, 258–267 (2010)
19. Wicks, I.P. & Roberts, A.W. Targeting GM-CSF in inflammatory diseases. Nat. Rev. Rheumatol. 12, 37–48 (2016)
20. Shiomi, A., Usui, T., Ishikawa, Y., Shimizu, M., Murakami, K. & Mimori, T. GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice. J. Immunol. 193, 849–859 (2014)
21. Lejeune, D., Dumoutier, L., Constantinescu, S., Kruijer, W., Schuringa, J.J. & Renauld, J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277, 33676–33682 (2002)
22. Brouwer, K.L. et al. Human ontogeny of drug transporters: review and recommendations of the Pediatric Transporter Working Group. Clin. Pharmacol. Ther. 98, 266–287 (2015)
23. Alcorn, J. & McNamara, P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin. Pharmacokinet. 41, 1077–1094 (2002)
24. Pottel, H., Hoste, L. & Delanaye, P. Abnormal glomerular filtration rate in children, adolescents and young adults starts below 75 mL/min/1.73 m(2). Pediatr. Nephrol. 30, 821–828 (2015)
25. Fridman, J.S. et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184, 5298–5307 (2010)
26. McInnes, I.B. & Siebert, S. Psoriatic arthritis — expanding options, exciting times? Acta Reumatol. Port. 39, 294–295 (2014)
27. Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507–518 (2014)
28. Qiao, Y. et al. Synergistic activation of inflammatory cytokine genes by interferon-gamma-induced chromatin remodeling and toll-like receptor signaling. Immunity 39, 454–469 (2013)
29. Ivashkiv, L.B. & Donlin, L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014)
30. Mostafavi, S. et al. Parsing the interferon transcriptional network and its disease associations. Cell 164, 564–578 (2016)
31. Keystone, E.C. et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann. Rheum. Dis. 74, 333–340 (2015)
32. Taylor, P.C. et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N. Engl. J. Med. 376, 652–662 (2017)
33. Siguier, M., Sellier, P. & Bergmann, J.F. BK-virus infections: a literature review. Med. Mal. Infect. 42, 181–187 (2012)
34. Knowles, W.A. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv. Exp. Med. Biol. 577, 19–45 (2006)
35. Rinaldo, C.H., Tylden, G.D. & Sharma, B.N. The human polyomavirus BK (BKPyV): virological background and clinical implications. APMIS 121, 728–745 (2013)
36. Polo, C., Perez, J.L., Mielnichuck, A., Fedele, C.G., Niubo, J. & Tenorio, A. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin. Microbiol. Infect. 10, 640–644 (2004)
37. Zhou, W. et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol. 20, 379–388 (2007)
38. Krutzik, P.O., Irish, J.M., Nolan, G.P. & Perez, O.D. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin. Immunol. 110, 206–221 (2004)